Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Two large independent studies raise further concern over increased risk of serious cardiac valve disease in patients treated for Parkinson's disease with ergoline dopamine agonists, pergolide and cabergoline.

Cardiac Valvular Disease Associated with the Dopamine Agonists Pergolide and Cabergoline